CARsgen^® Announces 2024 Interim Results

CARsgen Announces Enrollment Completion in China GC/GEJ Pivotal Phase II Clinical Trial of the First-in-class Claudin18.2 CAR T (Satri-cel)

CARsgen Presents Phase II Results on Zevorcabtagene Autoleucel and First-in-human CT071 Results at EHA 2024

CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024

CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO

EHA Preview | CARsgen to Present Results of Zevorcabtagene Autoleucel and CT071 at 2024 EHA

CARsgen Submitted Responses to FDA Observations

ASCO Preview | CARsgen to Present Results of CT041 at 2024 ASCO

CARsgen Announced 2023 Annual Results

NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma